CAS 1187594-09-7 appears in our catalog under these names: Baricitinib, Baricitinib, >95% (HPLC), Baricitinib/ 99.79% (existing batch purity), Baricitinib (LY3009104, INCB028050), Baricitinib, 98.00%. Offered by: Chemat Brand, TRC, Mikromol, TargetMol, GLPBio. Available pack sizes: on request, 10mg, 50mg, 250mg, 5mg, 25mg, 100mg, 200mg.
Baricitinib is a pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidine substituted by a 1-[3-(cyanomethyl)-1-(ethanesulfonyl)azetidin-3-yl]-1H-pyrazol-4-yl group at position 5. It is an FDA approved selective Janus Kinase 1 and 2 (JAK1 and JAK2) inhibitor used for the treatment of rheumatoid arthritis. It has a role as an antiviral agent, an immunosuppressive agent, an antirheumatic drug, an anti-inflammatory agent and an EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor. It is a nitrile, a member of pyrazoles, a sulfonamide, a pyrrolopyrimidine and a member of azetidines.
Source: ChEBI
| Molecular formula | C16H17N7O2S |
|---|---|
| Molecular weight | 371.4 g/mol |
| IUPAC name | 2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile |
| InChIKey | XUZMWHLSFXCVMG-UHFFFAOYSA-N |
| SMILES | CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3 |
Computed by PubChem (NCBI)